共 121 条
[21]
Kim TY(2020)A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Gastric Cancer 23 510-9
[22]
Kang JH(2019)Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit MAbs 11 1443-51
[23]
Lee SI(2020)Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase ib clinical trial BMC Cancer 20 760-8
[24]
Lim DH(2021)Clinical study of Sintilimab as Second-Line or above therapy in patients with Advanced or metastatic gastric Cancer: a retrospective study Front Oncol 11 741865-106
[25]
Thuss-Patience PC(2019)Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Ann Oncol 30 250-85
[26]
Kretzschmar A(2020)Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: cohort 1 data from the KEYNOTE-659 phase IIb study Eur J Cancer 129 97-80
[27]
Bichev D(2020)Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity Exp Mol Med 52 1475-15
[28]
Hironaka S(2010)Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer Cancer Res 70 6171-74
[29]
Ueda S(2014)Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Nat Med 20 607-77
[30]
Yasui H(2009)Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 162-23